Velvio develops state-of-the-art antisense oligonucleotide drugs that exert their effect by decreasing synthesis of a single protein. In Velvio's development concept, these drugs are used to restore organ repair functions, initially for the treatment of rare "orphan" diseases in neurodegeneration and lung diseases; the first target indications are ALS and IPF, both diseases are always life-threatening and so far, not treatable for their cause. There are few approved treatment options available with limited efficacy. In addition, Velvio's antisense candidate library offers opportunities in immune oncology and new treatment concepts for brain and liver tumors. Here too, initial R&D results are quite promising.

Investment Case with De-risking Pipeline Development

Velvio’s NVP-Products R&D Preclinical Phase Ib / IIa Phase IIb / III MAA3
  • Completed
  • Next steps
  • * Velvio value inflection point


  • Idiopathic pulmonary fibrosis (IPF)
  • Bronchopulmonary dysplasia (BPD)
  • Market Authorization Application
IP-Protected NVP Portfolio (>200 candidates)          
NVP-13: ALS / Neurodegeneration       * 2024
NVP-13/-19: Lung IPF1/BPD2 (pediatric)   *   * 2024
Further options          
NVP-X: Liver Diseases   *     2025
NVP-Y: Oncology   *     202X



Velvio GmbH

Am Biopark 11
93053 Regensburg | Germany

+49 (0) 941 463 747-37